Dec 2020 // The agreement will accelerate commercialization of its AI mental health platform, PREDICTIX, in Australia, New Zealand and the USA, pending regulatory approval.
Taliaz, a mental health startup harnessing artificial intelligence (AI) to revolutionize mental health treatment and management, has announced that it has entered into a three-year partnership agreement with molecular diagnostics leader, Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the ‘Company’) for the distribution of its PREDICTIX products, Genetics and Digital, in Australia, New Zealand and the USA, pending regulatory approval.
The new agreement will start in the field of depression and accelerate global commercialization of Taliaz’s pioneering decision-support and management platform, while supporting GTG to expand its product offering and the establishment of a mental health vertical. This announcement follows Taliaz’s recent $2.7 Million EU Horizon funding awarded earlier this month.
As part of the binding agreement, Taliaz will grant GTG exclusive distribution rights to its PREDICTIX products within Australia and New Zealand for a period of three years and non-exclusive distribution rights within the United States.
Dekel Taliaz, CEO and Co-founder of Taliaz said, “We are thrilled to partner with Genetic Technologies, world-leaders in the genetic risk assessment space. This new partnership will enable rapid commercialization of PREDICTIX to help more depression sufferers in Australia, New Zealand and the USA, while adding a complementary and advanced mental health solution to GTG’s growing suite of DNA tests.”